Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
The closing price of Recursion Pharmaceuticals Inc (NASDAQ: RXRX) was $4.83 for the day, down -2.23% from the previous closing price of $4.94. In other words, the price has decreased by -$2.23 from its previous closing price. On the day, 15.76 million shares were traded. RXRX stock price reached its highest trading level at $5.03 during the session, while it also had its lowest trading level at $4.83.
Ratios:
Our analysis of RXRX’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 3.58 and its Current Ratio is at 3.58. In the meantime, Its Debt-to-Equity ratio is 0.10 whereas as Long-Term Debt/Eq ratio is at 0.07.
On May 22, 2023, Morgan Stanley started tracking the stock assigning a Equal-Weight rating and target price of $8. On March 16, 2023, Needham started tracking the stock assigning a Buy rating and target price of $17.Needham initiated its Buy rating on March 16, 2023, with a $17 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Aug 18 ’25 when Khan Najat sold 36,599 shares for $5.52 per share. The transaction valued at 202,173 led to the insider holds 668,197 shares of the business.
Khan Najat bought 36,599 shares of RXRX for $202,169 on Aug 18 ’25. On Aug 11 ’25, another insider, Gibson Christopher, who serves as the Chief Executive Officer of the company, sold 500,300 shares for $5.28 each. As a result, the insider received 2,641,584 and left with 1,004,619 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RXRX now has a Market Capitalization of 2096954112 and an Enterprise Value of 1710201600. For the stock, the TTM Price-to-Sale (P/S) ratio is 32.46 while its Price-to-Book (P/B) ratio in mrq is 2.27. Its current Enterprise Value per Revenue stands at 26.475 whereas that against EBITDA is -2.917.
Stock Price History:
The Beta on a monthly basis for RXRX is 0.91, which has changed by -0.36530882 over the last 52 weeks, in comparison to a change of 0.14460516 over the same period for the S&P500. Over the past 52 weeks, RXRX has reached a high of $12.36, while it has fallen to a 52-week low of $3.79. The 50-Day Moving Average of the stock is -11.37%, while the 200-Day Moving Average is calculated to be -21.27%.
Shares Statistics:
RXRX traded an average of 27.90M shares per day over the past three months and 18346830 shares per day over the past ten days. A total of 425.48M shares are outstanding, with a floating share count of 332.34M. Insiders hold about 23.45% of the company’s shares, while institutions hold 55.45% stake in the company. Shares short for RXRX as of 1753920000 were 117535748 with a Short Ratio of 4.21, compared to 1751241600 on 117408745. Therefore, it implies a Short% of Shares Outstanding of 117535748 and a Short% of Float of 29.060000000000002.
Earnings Estimates
The company has 6.0 analysts who recommend its stock at the moment. The consensus estimate for the next quarter is -$0.36, with high estimates of -$0.26 and low estimates of -$0.42.
Analysts are recommending an EPS of between -$1.29 and -$1.8 for the fiscal current year, implying an average EPS of -$1.58. EPS for the following year is -$1.28, with 9.0 analysts recommending between -$0.81 and -$1.6.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 5 analysts. It ranges from a high estimate of $23.9M to a low estimate of $16M. As of the current estimate, Recursion Pharmaceuticals Inc’s year-ago sales were $26.08MFor the next quarter, 5 analysts are estimating revenue of $17.7M. There is a high estimate of $20.6M for the next quarter, whereas the lowest estimate is $16M.
A total of 9 analysts have provided revenue estimates for RXRX’s current fiscal year. The highest revenue estimate was $95.5M, while the lowest revenue estimate was $48.35M, resulting in an average revenue estimate of $69.68M. In the same quarter a year ago, actual revenue was $58.84MBased on 9 analysts’ estimates, the company’s revenue will be $97.31M in the next fiscal year. The high estimate is $208.4M and the low estimate is $45M.
